✦ LIBER ✦

Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)

✍ Scribed by Wirth, Manfred; Tammela, Teuvo; Cicalese, Virgilio; Gomez Veiga, Francisco; Delaere, Karl; Miller, Kurt; Tubaro, Andrea; Schulze, Matthias; Debruyne, Frans; Huland, Hartwig; Patel, Anup; Lecouvet, Frederic; Caris, Christien; Witjes, Wim

Book ID: 122149515
Publisher: Elsevier Science
Year: 2015
Tongue: English
Weight: 749 KB
Volume: 67
Category: Article
ISSN: 0302-2838
DOI: 10.1016/j.eururo.2014.02.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The risk of renal impairment in hormone-

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid

✍ William K. Oh; Kevin Proctor; Mari Nakabayashi; Carolyn Evan; Lauren K. Tormey; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Open-label trial evaluating the safety a

Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases

✍ Thomas J. Polascik; Robert W. Given; Charles Metzger; Sydney R. Julian; James C. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 133 KB

810 ORAL Risk and risk factors of renal

810 ORAL Risk and risk factors of renal impairment in hormone refractory prostate cancer (HPRC) patients with bone metastases (BM) treated with Zoledronic Acid (ZA)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 429 KB

MP-08.12: One single dose of zoledronic

MP-08.12: One single dose of zoledronic acid (Zometa) annually can prevent bone mineral density (BMD) in patients with prostate cancer treated with LHRH: early results of a randomized trial

✍ A. Lekas; M. Chrisofos; I. Fokitis; A. Balangas; A. Kollias; C. Deliveliotis 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 87 KB

715 EFFECTIVENESS OF ZOLEDRONIC ACID FOR

715 EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF BONE METASTASES IN HIGH RISK PROSTATE CANCER PATIENTS. A RANDOMISED, OPEN LABEL, MULTICENTER STUDY OF THE EUROPEAN ASSOCIATION OF UROLOGY (EAU) IN COOPERATION WITH THE SCANDINAVIAN PROSTATE CANCER GROUP (SPCG) AND THE ARBEITSGEMEINSCHAFT UROLOGISCHE ONKOLOGIE (AUO). A FIRST REPORT OF THE “ZEUS” STUDY

✍ M.P. Wirth; T. Tarmimela; W. Witjes 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 320 KB

176 NUMBER NEEDED TO TREAT AND RISK BENE

176 NUMBER NEEDED TO TREAT AND RISK BENEFIT ANALYSIS OF DENOSUMAB VERSUS ZOLEDRONIC ACID IN THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER PATIENTS WITH BONE METASTASES

✍ Xie, Jipan; Diener, Melissa; Wu, Eric; Sorg, Rachael; Yu, Andrew; Namjoshi, Madh 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 47 KB